Process optimization of mRNA purification for vaccines and therapeutic applications

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

The success of mRNA vaccines in combating a global pandemic highlights the power of this technology not only to revolutionize prophylactic treatments for infectious diseases, but also to treat other diseases such as cancer. Critical to bringing these medicines to patients is an efficient, effective, and scalable downstream production process.

One of the molecular hallmarks of mRNA is its 3-prime poly-A tail, consisting of many consecutive adenylate bases. Leveraging fundamental A:T base complementarity, an affinity resin was developed to simplify affinity capture of in vitro transcribed mRNA.

This webinar will address the development, characterization, and optimization of an mRNA capture step using POROS Oligo(dT)25 resin. mRNA research techniques have developed over several decades, and associated traditional purification methods have proven challenging to scale. A newer affinity solution leveraging the rigid POROS backbone with its linear pressure-flow relationship enables a consistent purification platform, from process development through to clinical manufacturing.

• Considerations for selection of affinity capture step in the downstream purification of mRNA
• Performance data of the POROS Oligo(dt)25 affinity resin under various conditions and feeds
• Practical approaches via Design of Experiments (DoE) to optimize binding capacity and yield an effective capture step for mRNA vaccines and therapeutics
• Effective strategies to control cost of goods including resin cleaning and re-use conditions, and performance data

Chantelle Gaskin

Staff Scientist, Field Applications at Thermo Fisher Scientific

Chantelle Gaskin is a Field Applications Staff Scientist, specializing in protein and viral vector purification and downstream process development. She held leadership positions at Applied Genetic Technology Corporation and Brammer Bio, prior to joining the Thermo Fisher Scientific Bioproduction Division in 2020. With over 10 years of experience in gene therapy, Chantelle has accumulated comprehensive knowledge of standard industry practices and regulatory standards, applying this knowledge to advance development of therapies for a variety of indications including ocular, CNS and systemic disease.

Chantelle holds a Master’s degree in Chemistry from University of Florida and a Bachelor’s in Chemistry from Smith College.

Watch now

SPEAKERS

Chantelle Gaskin

Staff Scientist, Field Applications at Thermo Fisher Scientific

You might also like

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya

1 August

in 30

Days

Register

Characterization and release testing for AAV therapies: empty/partial/full capsid analysis and impact on potency

K Doucette, F Voss, R Vancini

25 July

in 23

Days

Register

Development of a non-viral gene delivery platform for CAR-T manufacturing

S Feldman, J Brady, D Nguyen

24 July

in 22

Days

Register

Supporting efficacy and scaling with a next-generation T cell AOF formulation medium

Alan Gutowski, Joanna Kern

23 July

in 21

Days

Register

Navigating cold chain complexity with innovative solutions

Susan Li

17 July

in 15

Days

Register